Flag of the European Union EU Clinical Trials Register Help

Clinical trials for "overactive bladder"

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

  • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).


    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
    Select Country:
    Select Age Range:
    Select Trial Status:
    Select Trial Phase:
    Select Gender:
    Select Date Range:
    to
    Select Rare Disease:
    IMP with orphan designation in the indication
    Orphan Designation Number:
    Results Status:
    Clear advanced search filters
     
    41 result(s) found for: "overactive bladder". Displaying page 1 of 3.
    1  2  3  Next»
    EudraCT Number: 2010-024271-10 Sponsor Protocol Number: V00162GL203 Start Date*: 2011-07-06
    Sponsor Name:PIERRE FABRE MEDICAMENT
    Full Title: Urodynamic effect of one single vaginal application of 2 mL of V0162 gel (0.8%) in post-menopausal women with overactive bladder
    Medical condition: Overactive Bladder symptoms.
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: PL (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2010-022611-19 Sponsor Protocol Number: XEN-D0501-CL-03 Start Date*: 2011-01-07
    Sponsor Name:Xention Limited
    Full Title: A Phase 2a, multicentre, parallel-group, randomised, double-blind, placebo-controlled study to evaluate the safety and efficacy of 2 doses of XEN-D0501 in the treatment of idiopathic overactive bla...
    Medical condition: Overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    12.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) BE (Completed) EE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-004249-33 Sponsor Protocol Number: A8881001 Start Date*: 2005-12-14
    Sponsor Name:Pfizer Limited
    Full Title: A phase 2, 26 week, multicenter, randomized double blind, placebo controlled, crossover study evaluating the efficacy and safety of tolterodine, pregabalin and a tolterodine-pregabalin combination ...
    Medical condition: Overactive bladder syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10059617 LLT
    Population Age: Adults Gender: Female
    Trial protocol: GB (Completed) SK (Completed) SE (Completed) CZ (Completed) LT (Completed)
    Trial results: View results
    EudraCT Number: 2006-004854-26 Sponsor Protocol Number: ELB245201-06 Start Date*: 2007-02-16
    Sponsor Name:elbion AG
    Full Title: A multicenter, randomized, double-blind, parallel group, phase II, forced dose titration study to investigate the efficacy and safety of 400mg and 600mg flupirtine (ELB245) given once daily for 12 ...
    Medical condition: Incontinent Overactive Bladder
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 Overactive bladder LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) SE (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2006-006872-39 Sponsor Protocol Number: DIMS4 Start Date*: 2008-01-04
    Sponsor Name:Daval International Limited
    Full Title: A randomised, double-blind, placebo controlled study of AIMSPRO in Multiple Sclerosis
    Medical condition: Overactive Bladder in Secondary Progressive Multiple Sclerosis and the other neurological symptoms associated with Secondary Progressive Multiple Sclerosis
    Disease: Version SOC Term Classification Code Term Level
    9.1 10063400 Secondary progressive multiple sclerosis LLT
    9.1 10059617 Overactive bladder LLT
    9.1 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2007-002999-34 Sponsor Protocol Number: Y-79-52120-126 Start Date*: 2007-12-04
    Sponsor Name:Ipsen Limited
    Full Title: A phase II, international, multi-centre, prospective, randomised, parallel-group, double-blind, dose-ranging, placebo-controlled, 12-week, princeps study to assess the efficacy and safety of a one ...
    Medical condition: Idiopathic overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    9.1 10020853 Hypertonic bladder LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) BE (Completed) FR (Completed) CZ (Completed) IT (Prematurely Ended) ES (Completed)
    Trial results: View results
    EudraCT Number: 2004-000609-23 Sponsor Protocol Number: BXL-6280213 Start Date*: 2004-06-25
    Sponsor Name:BIOXELL SPA
    Full Title: A randomized, double blind, placebo controlled, parallel-group study to determine the effect of BXL-628 in post-menopausal women with Overactive Bladder (OAB)
    Medical condition: overactive bladder
    Disease: Version SOC Term Classification Code Term Level
    6.1 10027300 HLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2006-001378-26 Sponsor Protocol Number: 40776ORII/05IA01 Start Date*: 2006-09-26
    Sponsor Name:Laboratorios SALVAT, S.A.
    Full Title: A Multicentre, Placebo Controlled, Randomised, Double-blind, Dose Ranging Study of SVT-40776 0.05 mg, 0.1 mg, 0.2 mg, Tolterodine 4 mg and Placebo Daily Doses for 4 Weeks in Patients Suffering from...
    Medical condition: Overactive bladder (OAB)
    Disease: Version SOC Term Classification Code Term Level
    8.1 10059617 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Completed) CZ (Completed) HU (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2014-004161-24 Sponsor Protocol Number: A0221066 Start Date*: 2015-03-24
    Sponsor Name:Pfizer Inc. 235 East 42nd Street, New York, NY 10017
    Full Title: An Open-Label, Dose-Escalating Study of the Pharmacokinetics, Safety and Tolerability of Fesoterodine in Pediatric Overactive Bladder Patients Aged 8-17 Years
    Medical condition: Overactive bladder (OAB) and Neurogenic Detrusor Over activity
    Disease:
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2005-001250-24 Sponsor Protocol Number: 850 1016-1562 Start Date*: 2005-08-16
    Sponsor Name:APOGEPHA Arzneimittel GmbH
    Full Title: Proof-of-Concept Trial of NS-8 in 3 doses: Comparison of efficacy and tolerability in patients with overactive bladder.
    Medical condition: Subjects with overactive bladder syndrome with urinary urge.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021137-32 Sponsor Protocol Number: CSAF312A2202 Start Date*: 2011-03-14
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multi-center, double-blind, randomized, placebocontrolled, cross-over study to evaluate the efficacy, safety and tolerability of SAF312 in subjects with neurogenic detrusor overactivity due to sp...
    Medical condition: Neurogenic detrusor overactivity due to spinal cord injury
    Disease: Version SOC Term Classification Code Term Level
    14.1 10038359 - Renal and urinary disorders 10020853 Hypertonic bladder PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-004995-20 Sponsor Protocol Number: 05/SUR/3360E Start Date*: 2006-06-08
    Sponsor Name:R and D Department, Cardiff and the Vale NHS Trust
    Full Title: A Prospective, Single-Arm, Open-label Study to Investigate the Efficacy and Safety of Intravesical Injection of Botulinum Toxin Type-A (500 Units Dysport®) for the Management of Idiopathic Overacti...
    Medical condition: Idiopathic Overactive bladder syndrome
    Disease: Version SOC Term Classification Code Term Level
    8.0 10029279 LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-003929-30 Sponsor Protocol Number: 1 Start Date*: 2022-10-14
    Sponsor Name:Ligalli BV
    Full Title: INFLUENCE OF OXYBUTYNIN - MEDRING LIGALLI ON OVERACTIVE BLADDER SYMPTOMS IN WOMEN
    Medical condition: urinary urge incontinence
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-006201-12 Sponsor Protocol Number: 003 Start Date*: 2007-01-10
    Sponsor Name:MERCK SHARP DOHME
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo- and Active-Controlled, Parallel-Group, Dose-Ranging Study of MK-0594 in Patients With Overactive Bladder
    Medical condition: overactove bladder
    Disease: Version SOC Term Classification Code Term Level
    6.1 10046494 PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2005-005431-97 Sponsor Protocol Number: B3P104833 Start Date*: 2006-03-14
    Sponsor Name:GlaxoSmithKline Research & Development
    Full Title: An Eight-Week Randomized, Double-Blind, Placebo-Controlled, Parallel Group Proof of Concept Dose Ranging Study to Assess the Efficacy, Safety and Tolerability as well as the Pharmacokinetic Profile...
    Medical condition: Overactive bladder (OAB)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FI (Completed) DE (Completed) SI (Completed) LV (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-005868-93 Sponsor Protocol Number: AV608-106 Start Date*: 2006-05-15
    Sponsor Name:AVERA PHARMACEUTICALS INC.
    Full Title: A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial to Investigate the Safety and Efficacy of AV608 in Subjects with Idiopathic Detrusor Overactivity
    Medical condition: Idiopathic Detrusor Overactivity (Overactive Bladder)
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed) NL (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-023210-31 Sponsor Protocol Number: Y52-52120-155 Start Date*: 2012-02-24
    Sponsor Name:Ipsen Innovation
    Full Title: A PHASE IIA, MULTICENTRE, DOUBLE BLIND, SINGLE DOSE, PARALLEL GROUP, PLACEBO CONTROLLED, CLINICAL PILOT STUDY TO ASSESS THE EFFICACY AND SAFETY OF SINGLE DOSE, INTRA-DETRUSOR INJECTIONS OF 750 UNIT...
    Medical condition: NEUROGENIC DETRUSOR OVERACTIVITY
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004857 10012547 Detrusor hyperreflexia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) AT (Completed) IT (Completed) LT (Completed) CZ (Completed)
    Trial results: View results
    EudraCT Number: 2009-016800-22 Sponsor Protocol Number: I1A-MC-BPAE Start Date*: 2010-05-14
    Sponsor Name:Eli Lilly and Company Limited
    Full Title: A Phase 2 Clinical Study to Evaluate Daily Oral Doses of LY500307 for 24 weeks in Men with Lower Urinary Tract Symptoms (LUTS) and Prostatic Enlargement Secondary to Benign Prostatic Hyperplasia (B...
    Medical condition: Benign prostatic hyperplasia
    Disease: Version SOC Term Classification Code Term Level
    13.1 10038604 - Reproductive system and breast disorders 10004446 Benign prostatic hyperplasia PT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: DE (Completed) FR (Completed) IT (Prematurely Ended) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2006-006656-35 Sponsor Protocol Number: A3711047 Start Date*: 2007-06-12
    Sponsor Name:Pfizer Ltd
    Full Title: A Multi-center, Randomized, Parallel Group, Double-blind, Placebo Controlled Estimation Study to Assess the Efficacy and Safety of Modified Release UK-369,003 in the Treatment of Men with Storage L...
    Medical condition: Storage male lower urinary tract symptoms (LUTS) with and without erectile dysfunction (ED).
    Disease: Version SOC Term Classification Code Term Level
    9.1 10046566 Urinary tract disorder LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: FR (Completed) FI (Completed) DE (Completed) GB (Completed) GR (Completed) LV (Completed) IT (Completed) SK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2007-003407-12 Sponsor Protocol Number: 191622-518 Start Date*: 2008-02-19
    Sponsor Name:Allergan Limited
    Full Title: A Multicenter, Double-Blind, Randomized, Placebo-Controlled, Parallel-Group Study to Explore the Dose Dependent Response to Three Dose Levels of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin ...
    Medical condition: Neurogenic detrusor overactivity as a result of spinal cord injury, in patients with urinary incontinence, who have not been adequately managed with anticholinergic therapy.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10029279 Neurogenic bladder PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Prematurely Ended) GR (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:44:43 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA